SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, citing Palantirs sovereign-AI and customized-software opportunities, coincided with a rally to fresh highs. Bulls celebrated the breakout and speculated about a short squeeze, while bears warned that the valuation is stretched and a pullback may follow.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is drawing attention as a Bitcoin-native Runes memecoin, with holders promoting its Bitcoin connection and community-driven launch while saying they are accumulating through a prolonged pullback. Critics counter that trading is thin and the token is heavily hyped, leaving the discussion divided between long-term conviction and concerns about liquidity and downside risk.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Repeated analyst downgrades and price-target cuts amid a steep, volatile pullback are dominating discussion ahead of AppLovins upcoming results. Bulls argue the decline overlooks the companys growth and cash generation, while frustrated holders debate whether the weakness reflects excessive analyst pessimism or genuine risks to the outlook.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics scheduled data presentations at MSToronto, especially a late-breaking oral presentation of initial Phase 1 azer-cel findings in progressive MS, alongside BRIUMVI data. Traders view the presentation slot as encouraging and are positioning for potential news, but the results are not yet known; discussion also points to upcoming subcutaneous BRIUMVI data and remains divided between bullish catalyst expectations and frustration with choppy trading.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines volatile pullback has traders debating whether a shelf registration signals dilution; some fear added selling pressure, while others say it only registers existing warrant-holder shares rather than a new company offering. The discussion also reflects anticipation for upcoming earnings and disagreement over whether the recent weakness is a buying opportunity or further downside.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is drawing attention after a strong, high-volume run ahead of founder Patrick Soon-Shiongs scheduled Piper Sandler oncology fireside chat, where he plans to discuss trial progress. Traders are speculating about additional clinical, commercial, or partnership news and a possible short squeeze, but partnership rumors remain unverified.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA review documents showing a comparatively weak response rate for daraxonrasib in the KRAS G12D pancreatic-cancer subgroup have raised fresh concerns about efficacy and competition from more selective RAS inhibitors. Traders debate whether the subgroup response data signal a real weakness or are less important than the drugs broader survival results, while some view the selloff as an overreaction.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks September mining update, move to quarterly operational reporting, and fully funded Meta-backed data-center project are driving discussion. Holders point to the AI infrastructure opportunity and Bitcoin holdings, while many traders remain frustrated by the share-price decline and question mining economics, financing costs, and reduced reporting frequency.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

ARK Invests repeated purchases of NTLA are drawing attention, with bullish traders treating the accumulation as a vote of confidence while skeptics caution that it does not guarantee a turnaround. The discussion also centers on FDA priority review of lonvo-z for hereditary angioedema and the approaching commercialization decision, set against concerns about financing, adoption, and volatile trading.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins rally has traders focusing on speculation around a potential Grayscale ETF and the projects proof-of-humanity use case as AI agents and bots proliferate; some also point to Eightcos WLD holdings as a source of attention. Bullish breakout and short-squeeze talk is countered by concerns about volatility, token supply, and promotional hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.

Is it the Right Time to Add Phibro Stock to Your Portfolio?

PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.

Bruker Gains 66.3% in a Year: What's Driving the Rally?

BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.

Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies

VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.

Reasons to Add Globus Medical Stock to Your Portfolio Now

GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.

Charles River Gains 75.8% in a Year: What's Driving the Rally?

CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.

Is This the Right Time to Add TMO Stock to Your Portfolio?

Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Veracyte Inc

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

VCYT News